The 36-month beta value for ACIU is at 1.58. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ACIU is 61.06M, and currently, shorts hold a 2.27% of that float. The average trading volume for ACIU on June 25, 2025 was 147.02K shares.
ACIU) stock’s latest price update
AC Immune SA (NASDAQ: ACIU) has experienced a rise in its stock price by 246043 compared to its previous closing price of 1.83. However, the company has seen a gain of 8.51% in its stock price over the last five trading days. zacks.com reported 2025-04-30 that AC Immune (ACIU) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.21 per share a year ago.
ACIU’s Market Performance
AC Immune SA (ACIU) has experienced a 8.51% rise in stock performance for the past week, with a 24.19% rise in the past month, and a -0.71% drop in the past quarter. The volatility ratio for the week is 8.53%, and the volatility levels for the past 30 days are at 5.64% for ACIU. The simple moving average for the past 20 days is 11.95% for ACIU’s stock, with a -17.82% simple moving average for the past 200 days.
Analysts’ Opinion of ACIU
Many brokerage firms have already submitted their reports for ACIU stocks, with BTIG Research repeating the rating for ACIU by listing it as a “Buy.” The predicted price for ACIU in the upcoming period, according to BTIG Research is $8 based on the research report published on May 31, 2024 of the previous year 2024.
ACIU Trading at 21.79% from the 50-Day Moving Average
After a stumble in the market that brought ACIU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.27% of loss for the given period.
Stock Fundamentals for ACIU
Current profitability levels for the company are sitting at:
- -1.83 for the present operating margin
- 0.39 for the gross margin
The net margin for AC Immune SA stands at -1.84. The total capital return value is set at -0.46. Equity return is now at value -43.31, with -27.33 for asset returns.
Based on AC Immune SA (ACIU), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at 8.89. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -342.25.
Currently, EBITDA for the company is -48.62 million with net debt to EBITDA at 0.3. When we switch over and look at the enterprise to sales, we see a ratio of 5.4. The receivables turnover for the company is 9.71for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.53.
Conclusion
In conclusion, AC Immune SA (ACIU) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
